跳转至内容
Merck
所有图片(1)

文件

47127-U

Supelco

胆固醇 溶液

certified reference material, 10 mg/mL in chloroform

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C27H46O
CAS号:
57-88-5
分子量:
386.65
MDL號碼:
MFCD00003646
分類程式碼代碼:
85151701
eCl@ss:
39023139
PubChem物質ID:
329757293
NACRES:
NA.24

等級

certified reference material
TraceCERT®

品質等級

100

產品線

TraceCERT®

形狀

liquid

CofA

current certificate can be downloaded

包裝

ampule of 1 mL

濃度

10 mg/mL in chloroform

技術

HPLC: suitable
gas chromatography (GC): suitable

應用

food and beverages

格式

single component solution

儲存溫度

-10 to -25°C

SMILES 字串

[H][C@@]12CC=C3C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]4(C)[C@H](CC[C@@]24[H])[C@H](C)CCCC(C)C

InChI

1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1

InChI 密鑰

HVYWMOMLDIMFJA-DPAQBDIFSA-N

基因資訊

human ... POLA1(5422) , TOP2A(7153)
rat ... Ar(24208) , Polb(29240)

正在寻找类似产品? 访问 产品对比指南

相关类别

應用

有关合适的仪器技术的更多信息，请参阅产品′的检验报告。想要获得更多支持，请联系技术服务部。

其他說明

该认证标准物质（CRM）根据ISO 17034 和 ISO/IEC 17025进行生产和认证。有关此CRM使用的所有信息均可在检验报告上找到。

法律資訊

TraceCERT is a registered trademark of Merck KGaA, Darmstadt, Germany

象形圖

Skull and crossbonesHealth hazard
GHS06,GHS08

訊號詞

Danger

危險分類

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

標靶器官

Central nervous system

儲存類別代碼

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

個人防護裝備

Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number
LRAD3096
LRAC5634
LRAC0094
XA19426V
XA19425V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Yori Ozaki et al.
The British journal of nutrition, 114(9), 1410-1418 (2015-09-04)
Protein malnutrition promotes hepatic steatosis, decreases insulin-like growth factor (IGF)-I production and retards growth. To identify new molecules involved in such changes, we conducted DNA microarray analysis on liver samples from rats fed an isoenergetic low-protein diet for 8 h.
Peter Libby et al.
Immunity, 38(6), 1092-1104 (2013-07-03)
According to the traditional view, atherosclerosis results from a passive buildup of cholesterol in the artery wall. Yet, burgeoning evidence implicates inflammation and immune effector mechanisms in the pathogenesis of this disease. Both innate and adaptive immunity operate during atherogenesis
Frederick J Raal et al.
Lancet (London, England), 385(9965), 331-340 (2014-10-06)
Heterozygous familial hypercholesterolaemia is characterised by low cellular uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature cardiovascular disease. Despite intensive statin therapy, with or without ezetimibe, many patients are unable to achieve recommended target levels of LDL
Daniel I Swerdlow et al.
Lancet (London, England), 385(9965), 351-361 (2014-09-30)
Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target. We used single nucleotide polymorphisms in the HMGCR
Lingyun Lu et al.
American heart journal, 167(5), 683-689 (2014-04-29)
We previously found that the use of ezetimibe increased rapidly with different patterns between the United States (US) and Canada prior to the landmark Ezetimibe and Simvastatin in Hypercholesterolemia Enhance Atherosclerosis Regression (ENHANCE) trial, which was reported in January 2008
查看所有相关文献

实验方案

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门